MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fcvm.2026.1817298

Медицинская библиотека · Frontiers in cardiovascular medicine · 2026

A protocol for the impact of Tongmai Jiangtang capsules on the risk of cardiovascular and cerebrovascular events in metabolic syndrome.

Li Anxiang, Ma Yuntao, Chen Zhuhong, Lu Qiyun, Liu Chaolan, Zhou Peng, Liang Qingshun, Tao Yiming, Chen Meilin, Chen Zihan, Luo Fan, Lei Xingxing, Liu Shulin, Long Jieer, Xiao Hequn, Cui Chongsong, Ren Qiqi, Liu Yunwei, Zhong Tuoling, Liu Jiamiao, Fan Guanjie, Liu Ya, Hui Zhenliang, Chen Qiu, Liu Zhenjie

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Metabolic syndrome (MetS) significantly increases the risk of major adverse cardiovascular events (MACE), yet evidence-based complementary therapies remain limited. Tongmai Jiangtang Capsule (TJC), a traditional Chinese medicine (TCM) compound, has demonstrated benefits for glycolipid metabolism and microvascular complications, but its effect on hard cardiovascular and cerebrovascular (CCV) endpoints remains unconfirmed.

OBJECTIVE

To explore whether TJC, as an adjunctive therapy to standard care, reduces the incidence of MACE in patients with MetS and Qi deficiency-blood stasis syndrome.

METHODS

This is a randomized, double-blind, placebo-controlled, multicenter trial. A total of 530 participants aged ≥65 years, diagnosed with MetS and the TCM pattern of Qi Deficiency and Blood Stasis, and at high CCV risk, will be enrolled. They will be randomly assigned (1:1) to receive either TJC or a matched placebo, in addition to standard care, for 26 weeks, followed by a 26-week follow-up. The primary endpoint is the composite of 3P-MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). Secondary endpoints include metabolic parameters, vascular assessments, TCM symptom scores, and quality of life. Omics analyses will explore potential mechanisms. The trial was registered on ClinicalTrials.gov (NCT06908473).

DISCUSSION: This rigorously designed trial is expected to provide high-level evidence regarding the role of TJC in preventing CCV events in MetS. If positive, it will offer a novel, multi-target integrative treatment strategy. The findings will also advance the evidence-based evaluation of TCM compounds and contribute to chronic disease prevention goals. Regardless of the primary outcome, the mechanistic insights will inform future research on formula optimization and precision intervention.

CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/expert-search?term=NCT06908473, identifier, NCT06908473.

Для цитирования: Li Anxiang, Ma Yuntao, Chen Zhuhong, Lu Qiyun, Liu Chaolan, Zhou Peng, Liang Qingshun, Tao Yiming, Chen Meilin, Chen Zihan, Luo Fan, Lei Xingxing, Liu Shulin, Long Jieer, Xiao Hequn, Cui Chongsong, Ren Qiqi, Liu Yunwei, Zhong Tuoling, Liu Jiamiao, Fan Guanjie, Liu Ya, Hui Zhenliang, Chen Qiu, Liu Zhenjie. A protocol for the impact of Tongmai Jiangtang capsules on the risk of cardiovascular and cerebrovascular events in metabolic syndrome.. Frontiers in cardiovascular medicine. 2026. DOI: 10.3389/fcvm.2026.1817298.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.